{"id":289377,"date":"2026-10-06T11:39:34","date_gmt":"2026-10-06T06:09:34","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=289377"},"modified":"2026-10-06T11:39:34","modified_gmt":"2026-10-06T06:09:34","slug":"diagnostic-stocks-strong-roadmap","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/diagnostic-stocks-strong-roadmap\/","title":{"rendered":"3 Diagnostic Stocks With a Strong Future Roadmap: Dr. Lal PathLabs, Metropolis Healthcare and Vijaya Diagnostic Centre"},"content":{"rendered":"

Dr Lal PathLabs Rs 1,971.30, P\/E 60.54. Metropolis Rs 553.60, P\/E 56.76. Vijaya Diagnostic Rs 1,422.20, P\/E 78.19. Closing prices of 5 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Diagnostic stocks with the clearest long-term roadmaps today include Dr. Lal PathLabs in pathology tests through a large lab and collection centre network, Metropolis Healthcare in pathology and specialised diagnostics with a hub-and-spoke network and Vijaya Diagnostic Centre in pathology and radiology centres under one roof. FY26 revenue growth was 12.1% at Dr Lal PathLabs, 24.1% at Metropolis and 19.3% at Vijaya Diagnostic. P\/E stands at 60.54 for Dr Lal PathLabs (industry 64.07), 56.76 for Metropolis (industry 64.07) and 78.19 for Vijaya Diagnostic (industry 64.07). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.<\/p>\n<\/p><\/div>\n

Diagnostic stocks give investors exposure to the shift from treatment to testing in Indian healthcare. Results depend on test volumes, the number of collection centres and operating margin, which is why network reach and pricing matter as much as growth.<\/p>\n

This list covers three diagnostic chain stocks: Dr. Lal PathLabs for pathology tests through a large lab and collection centre network, Metropolis Healthcare for pathology and specialised diagnostics with a hub-and-spoke network and Vijaya Diagnostic Centre for pathology and radiology centres under one roof. Every figure comes from the latest reported financials and the 5 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n